Ligand source activities (1 row/activity)



Get vendors


Ligands (move mouse cursor over ligand name to see structure) Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb
ID		 #Vendors

 Reference
ligand		 Fold
selectivity		 # Tested
GPCRs		 Species

 p-value
(-log)		 Activity
Type		 Activity
Relation		 Activity
Value		 AssayType

 Assay
Description		 Source

 Mol
weight		 Rot
Bonds		 H don

 H acc

 LogP

 Smiles

 DOI
1499 2091 47 None -63 38 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
3779 2091 47 None -63 38 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
536 2091 47 None -63 38 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
CHEMBL434 2091 47 None -63 38 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
DB01064 2091 47 None -63 38 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
1499 2091 47 None -63 38 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
3779 2091 47 None -63 38 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
536 2091 47 None -63 38 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
CHEMBL434 2091 47 None -63 38 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
DB01064 2091 47 None -63 38 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R49 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
1183 3971 0 None 1 3 Human 3.3 pEC50 = 3.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 152 2 1 3 1.2 COc1cc(C=O)ccc1O 34307435
6412 3971 0 None 1 3 Human 3.3 pEC50 = 3.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 152 2 1 3 1.2 COc1cc(C=O)ccc1O 34307435
CHEMBL13883 3971 0 None 1 3 Human 3.3 pEC50 = 3.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 152 2 1 3 1.2 COc1cc(C=O)ccc1O 34307435
10930 3840 0 None - 1 Human 4.3 pEC50 = 4.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 467 6 10 14 -6.3 NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@H]([C@@H]([C@H]2O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)N)O)N)[C@@H](C[C@@H]1O)N 30011231
2684 3840 0 None - 1 Human 4.3 pEC50 = 4.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 467 6 10 14 -6.3 NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@H]([C@@H]([C@H]2O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)N)O)N)[C@@H](C[C@@H]1O)N 30011231
36294 3840 0 None - 1 Human 4.3 pEC50 = 4.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 467 6 10 14 -6.3 NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@H]([C@@H]([C@H]2O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)N)O)N)[C@@H](C[C@@H]1O)N 30011231
CHEMBL1747 3840 0 None - 1 Human 4.3 pEC50 = 4.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 467 6 10 14 -6.3 NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@H]([C@@H]([C@H]2O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)N)O)N)[C@@H](C[C@@H]1O)N 30011231
DB00684 3840 0 None - 1 Human 4.3 pEC50 = 4.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 467 6 10 14 -6.3 NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@H]([C@@H]([C@H]2O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)N)O)N)[C@@H](C[C@@H]1O)N 30011231
2882 1208 62 None -588 5 Human 4.4 pEC50 = 4.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 468 8 3 9 2.1 OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O 20022913
741 1208 62 None -588 5 Human 4.4 pEC50 = 4.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 468 8 3 9 2.1 OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O 20022913
7608 1208 62 None -588 5 Human 4.4 pEC50 = 4.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 468 8 3 9 2.1 OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O 20022913
CHEMBL428880 1208 62 None -588 5 Human 4.4 pEC50 = 4.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 468 8 3 9 2.1 OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O 20022913
DB01003 1208 62 None -588 5 Human 4.4 pEC50 = 4.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 468 8 3 9 2.1 OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O 20022913
12457 2505 123 None 3 2 Human 4.9 pEC50 = 4.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 216 1 0 4 2.5 COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2 26501253
4114 2505 123 None 3 2 Human 4.9 pEC50 = 4.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 216 1 0 4 2.5 COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2 26501253
CHEMBL416 2505 123 None 3 2 Human 4.9 pEC50 = 4.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 216 1 0 4 2.5 COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2 26501253
DB00553 2505 123 None 3 2 Human 4.9 pEC50 = 4.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 216 1 0 4 2.5 COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2 26501253
5074 3332 80 None -363 8 Human 5.2 pEC50 = 5.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 477 5 0 5 5.5 Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F 26501253
97 3332 80 None -363 8 Human 5.2 pEC50 = 5.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 477 5 0 5 5.5 Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F 26501253
CHEMBL267777 3332 80 None -363 8 Human 5.2 pEC50 = 5.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 477 5 0 5 5.5 Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F 26501253
DB12693 3332 80 None -363 8 Human 5.2 pEC50 = 5.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 477 5 0 5 5.5 Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F 26501253


Get vendors


Ligands (move mouse cursor over ligand name to see structure) Receptor Assay information Chemical information
Sel. page Similar-
ity		 Common
name		 GPCRdb
ID		 #Vendors

 Reference
ligand		 Fold
selectivity		 # Tested
GPCRs		 Species

 p-value
(-log)		 Activity
Type		 Activity
Relation		 Activity
Value		 Assay
Type		 Assay
Description		 Source

 Mol
weight		 Rot
Bonds		 H don

 H acc

 LogP

 Smiles

 DOI